Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07119021

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07119021
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07119021. Randomized; quadruple masking; primary purpose prevention. Start 2024-08-01 (actual); primary completion 2027-04-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
Acronym
EXCELLENT
Intervention (Drug)
Intravenous thrombolysis + edaravone
Intervention (Drug)
IV thrombolysis + placebo (control group)
Lead sponsor
Ruijun Ji (class: other)
Collaborator
Xing'an League People's Hospital (class: not stated)
Collaborator
The First Affiliated Hospital of Soochow University (class: other)
Collaborator
Nanyang Nanshi Hospital (class: other)
Collaborator
Nanjing Baixinyu Pharmaceutical Co., Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct07119021
Content hash
91d7d666242193692e4cb9e3add754b00b43d830ae1544f35863e4db00c97eb6